ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Gout in CKD Pregnancy: Avoid — animal studies show reproductive toxicity; limited human data

Febuxostat (CKD)

Brand names: Adenuric

Adult dose

Dose: 80 mg once daily; increase to 120 mg once daily if serum urate >360 micromol/L after 2-4 weeks
Route: Oral
Frequency: Once daily
Max: 120 mg/day
Xanthine oxidase inhibitor. Preferred over allopurinol in CKD stages 3-5 — hepatically metabolised, does not require renal dose adjustment (unlike allopurinol). Cover with colchicine or low-dose NSAIDs during initiation to prevent flares.

Paediatric dose

Route: Oral
Seek specialist opinion — not licensed in children

Dose adjustments

Renal

No dose adjustment required in mild-moderate renal impairment (major advantage over allopurinol). Caution in severe renal impairment (eGFR <30) — limited data but generally better tolerated than allopurinol.

Hepatic

Contraindicated in severe hepatic impairment; use with caution in moderate impairment

Clinical pearls

  • MHRA 2019 warning (FAST trial, Wilson et al. Lancet 2020): febuxostat associated with increased all-cause mortality and cardiovascular mortality vs allopurinol in patients with established IHD or congestive heart failure. CONTRAINDICATED in these patients.
  • FAST trial context: 6,128 patients with gout + CVD randomised to febuxostat vs allopurinol. CVD death 1.72% vs 1.28% per year with febuxostat. Absolute difference small but statistically significant.
  • Renal advantage: febuxostat is hepatically metabolised (primarily CYP1A2, 2C8, 2C9) — unlike allopurinol which requires significant renal dose reduction in CKD. Febuxostat doses do not change across CKD stages 1-4.
  • Flare prophylaxis: always start colchicine 500 mcg OD-BD (or low-dose naproxen if eGFR allows) for minimum 6 months when initiating urate-lowering therapy — mobilisation of urate crystals during treatment initiation triggers flares
  • Target serum urate: <360 micromol/L (6 mg/dL) for most patients; <300 micromol/L (<5 mg/dL) for tophaceous gout

Contraindications

  • Established ischaemic heart disease or congestive heart failure (MHRA 2019 — increased CV death in FAST trial)
  • Concomitant azathioprine or mercaptopurine (xanthine oxidase inhibition causes severe toxicity)
  • Concomitant theophylline
  • Hypersensitivity

Side effects

  • Gout flares (initiation period)
  • Liver enzyme elevation (monitor LFTs)
  • Diarrhoea
  • Nausea
  • Headache
  • Rash (including rare SJS/TEN)
  • Cardiovascular events (increased mortality in established CVD — FAST trial)

Interactions

  • Azathioprine/mercaptopurine — CONTRAINDICATED (xanthine oxidase inhibition causes fatal bone marrow toxicity — same interaction as allopurinol)
  • Theophylline — CONTRAINDICATED (increased theophylline toxicity)
  • Rosiglitazone — febuxostat may increase levels

Monitoring

  • Serum urate (2-4 weeks after dose changes, then annually)
  • LFTs (baseline and periodically)
  • Renal function
  • Gout flare frequency
  • Cardiovascular risk assessment before starting

Reference: BNFc; BNF 90; FAST Trial (Wilson et al. Lancet 2020); MHRA DSU 2019 (CV Risk); NICE CG56 (Gout); SPC Adenuric. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways